Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 3/20 | 0.44 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.43 |
| ▸ | CDK4 | P11802 | 1/20 | 0.43 |
| ▸ | CCND1 | P24385 | 1/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4533786 | 0.90 | ADORA2A (0.45) | DHFRCCNE2CDK4CCND1CCNE1 | |
| Trifluoroacetic Acid SCHEMBL4525618 | 0.85 | DHFR (0.52) | DHFRCCNE2CDK4CCND1CCNE1 | |
| Trifluoroacetic Acid SCHEMBL4528549 | 0.84 | DHFR (0.50) | DHFRCCNE2CCNE1CDK2PTPN1 | |
| Trifluoroacetic Acid SCHEMBL4533787 | 0.83 | HDAC2 (0.42) | DHFRCCNE2CDK4CCND1CCNE1 | |
| Trifluoroacetic Acid SCHEMBL4526540 | 0.83 | PTPN1 (0.48) | DHFRPTPN1 | |
| Trifluoroacetic Acid SCHEMBL4524510 | 0.81 | PTPN1 (0.50) | DHFRPTPN1 | |
| Trifluoroacetic Acid SCHEMBL4521116 | 0.81 | PTPN1 (0.48) | DHFRPTPN1 | |
| Trifluoroacetic Acid SCHEMBL4528055 | 0.81 | MAP4K4 (0.43) | DHFRPTPN1 | |
| Trifluoroacetic Acid SCHEMBL4517302 | 0.80 | PTPN1 (0.59) | DHFRPTPN1 | |
| Trifluoroacetic Acid SCHEMBL4533714 | 0.80 | PTPN1 (0.49) | DHFRPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812409-A1 | AMINOQUINAZOLINES COMPOUNDS | F. Hoffmann-Roche AG (CH) | 2007-08-01 | — | — | EP | claimed |
| WO-2006050843-A1 | AMINOQUINAZOLINES COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-18 | — | — | WO | claimed |
| US-20090105477-A1 | Quinazoline Protein Tyrosine Phosphatase Inhibitors | BERTHEL STEVEN JOSEPH | 2009-04-23 | — | — | US | disclosed |
| EP-1812409-A1 | AMINOQUINAZOLINES COMPOUNDS | F. Hoffmann-Roche AG (CH) | 2007-08-01 | — | — | EP | disclosed |
| US-20060211715-A1 | Quinazoline protein tyrosine phosphatase inhibitors | BERTHEL STEVEN J | 2006-09-21 | — | — | US | disclosed |
| WO-2006050843-A1 | AMINOQUINAZOLINES COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105477-A1 | Quinazoline Protein Tyrosine Phosphatase Inhibitors | PTPN5, PTPN1, PTPN7 | DHFR 2071/4885CCNE2 4173/4885CDK4 1631/4885 |
| US-20060211715-A1 | Quinazoline protein tyrosine phosphatase inhibitors | PTPN5, PTPN1, PTPN7 | DHFR 2071/4885CCNE2 4173/4885CDK4 1631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.